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Abstract
Background: The GABARAP family members (GABARAP, GABARAPL1/GEC1 and GABARAPL2 /GATE-16) are involved
in the intracellular transport of receptors and the autophagy pathway. We previously reported that GABARAPL1
expression was frequently downregulated in cancer cells while a high GABARAPL1 expression is a good prognosis
marker for patients with lymph node-positive breast cancer.
Methods: In this study, we asked using qRT-PCR, western blotting and epigenetic quantification whether the
expression of the GABARAP family was regulated in breast cancer by epigenetic modifications.
Results: Our data demonstrated that a specific decrease of GABARAPL1 expression in breast cancers was associated
with both DNA methylation and histone deacetylation and that CREB-1 recruitment on GABARAPL1 promoter was
required for GABARAPL1 expression.
Conclusions: Our work strongly suggests that epigenetic inhibitors and CREB-1 modulators may be used in the
future to regulate autophagy in breast cancer cells.
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Background
Autophagy is a cell process which regulates cell homeosta-
sis and survival by inducing the degradation and recycling
of intracellular components like protein aggregates or
organelles (such as damaged mitochondria) [1]. This
mechanism involves more than 40 proteins required for :
i) the formation of autophagosomes, ii) the fusion of
autophagosomes with lysosomes and/or, iii) the regulation
of autophagy flux. The role of autophagy in tumorigenesis
is controversial, even though evidence indicated that au-
tophagy is often downregulated in cancer cells. On one
hand, autophagy might protect against transformation of
non tumoral cells into cancer cells and in the other hand,
a loss of autophagy might help the cancer cells to escape
from type II cell death (also called autophagy cell death)
[2, 3]. Since induction of autophagy in cancer cells has also
been described to confer resistance to chemotherapeutive
agents, the co-administration of both alkyling agents and
autophagy inhibitors (such as hydroxychloroquine) could
improve the anti-tumoral response in these resistant cells
[4]. Among the proteins involved in autophagy, two sub-
families of homologs of the yeast Atg8 (Autophagy-related
8) have been described in mammals: i) the MAP-LC3s
(Microtubule-associated protein Light Chain 3) including
LC3A, LC3B and LC3C and, ii) the GABARAP (GABAA-
receptor-associated protein) family. The latter com-
prises 3 members: GABARAP, GABARAPL1/GEC1/
ATG8L (GABARAP-like protein 1/guinea-pig endometrial
glandular epithelial cells-1/Atg8-like protein) and GABAR-
APL2/GATE-16 (GABARAP-like protein 2/Golgi-associ-
ated ATPase enhancer of 16 kDa).
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GABARAP, GABARAPL1 and GABARAPL2 genes are
located on the human chromosomes, 17p13.12, 12p12.3
and 16q22.3 respectively, and are differentially expressed
in normal and pathological tissues. The GABARAP gene
has been described to be highly expressed in endocrine
tissues while the GABARAPL1 gene is predominantly
expressed in the central nervous system but they both
are underexpressed in a large variety of cancer cell lines
[5]. Nevertheless, the analysis of GABARAPL1 expres-
sion in a cohort of 256 breast adenocarcinoma revealed
that a low GABARAPL1 expression was correlated with
a high risk of metastasis, in particular for lymph node-
positive patients [6]. Despite these recent studies, the
regulation of the GABARAP family is still poorly under-
stood and the origin of their decreased expression in
tumor models remains unknown.
It is now recognized that epigenetic modifications con-
trol the expression of numerous genes via the regulation
of promoter accessibility to transcriptional factors. Both
DNA methylation and histone modifications affect the
level of chromatin compaction and it has been described
that epigenetically-mediated aberrant silencing of genes
are an important factor in the pathogenesis of cancers
including breast cancers (BC) [7, 8] Indeed, epigenetic
modifications can regulate the expression of a large
panel of genes involved in the hallmarks of cancer, such
as apoptosis, cell signaling, invasion and proliferation.
For example, the detection of the promoter methylation
of the tumor suppressor gene BRCA1, which is frequent
in BC and is associated with a decrease of BRCA1 ex-
pression, can help to predict the response to conven-
tional chemotherapies in triple negative BC patients
[9]. DNA methylation consists on the addition of a
methyl group on a cytosine in CpG islands. It is catalyzed
by DNA methyl transferases (DNMTs) and is unfavorable
to transcription. Following DNA replication and formation
of hemi-methylated DNA, the conservation of DNA
methylation on the neo-synthesized strand, is mainly proc-
essed by DNMT1 using the parental strand as a model.
This DNA methylation conservation is called maintaining
or inheritance DNA methylation. On the opposite, de novo
DNA methylation referred to the addition of DNA methy-
lation on both strands of DNA on previously unmethylated
loci is catalyzed by both DNMT3A and DNMT3B.
Besides DNA methylation, post-translational modifi-
cations of histones are also frequently associated to the
regulation of gene expression in cancers. Histones are
associated as octamers in nucleosomes (dimer of H2A,
H2B, H3 and H4 and a loop of 126 pb DNA) whose
compaction is regulated by post-translational modifications
such as phosphorylation, methylation or acetylation. The
local sum of these modifications is called the histone code
and determine the status of local chromatin compaction
(for a review see [10]). Histone methyl transferases (HMTs)
or histone demethylases (HDMs) respectively catalyze
the methylation or demethylation of histones leading to
different effects on transcription. For example, H3K9me
or K3K27me are negative marks while H3K4me is favor-
able to transcription. Acetylation, the most studied histone
modification, is processed by histone acetyl transferases
(HATs) and is associated with a local relaxed chromatin
and is therefore favorable to gene expression. On the op-
posite, the removal of acetyl groups from histones,
which is catalyzed by histone deacetylases (HDACs),
contributes to gene silencing.
Some recent studies also revealed that epigenetic mod-
ifications can regulate autophagy gene expression as well
as autophagy levels in both normal and cancer cells. For
example, HDACs play an essential role in the regulation
of autophagy: HDAC1 inhibition favors the conversion
of the soluble LC3B form (LC3B-I) to the membrane-
bound form of LC3B (LC3B-II), while the presence of
H4K16ac (catalyzed by hMOF (human ortholog of
drosophila males absent in the first)) in some ATGs genes,
is associated to a decrease of expression of these genes
[11, 12]. Moreover, HDAC6, an HDAC mainly localized in
the cytosol, has also been described to be involved in the
transport and maturation of autophagosomes [13]. DNA
methylation is also involved in autophagy regulation as
hypermethylation of several ATG genes has been described
in various cancers [13, 14]. For example, methylation of
BECN-1, a tumor suppressor gene, has been observed
in BC, while methylation of ATG16L2, LC3A, ULK2, or
BNIP3 has been suggested to be involved in the down-
regulation of autophagy in other cancers [15–19].
In order to characterize the regulation of GABARAP
gene family expression in cancer cells, we analyzed their
expression and the epigenetic modifications in the pro-
moters of these genes in in vitro human BC cell models.
Our data demonstrated that GABARAPL1 expression is
decreased in BC patients and BC cell line models. More-
over, both DNA methylation and deacetylation of histone
H3 in GABARAPL1 promoter were observed in these BC
cell line models while the inhibition of DNMTs and
HDACs using specific inhibitors restored GABARAPL1
expression in these cells. These data suggest that DNMTi
(DNMT inhibitors) and HDACi (HDAC inhibitors) could




Human samples were collected according to French laws
and the recommendations of the French National Com-
mittee of Ethics. Indeed, this study has been approved by
of the scientific committee of “the tumorothèque régionale
de Franche-Comté BB-0033-00024”. The samples and the
medical history of patients were encoded to protect
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patients confidentiality and used under protocols ap-
proved by the recommendations of the French national
Committee of Ethics. All human samples were collected
by Pr. Severine Valmary-Degano (Centre Hospitalo-
Universitaire, Besançon, France) at the “Tumorothèque
régionale de Franche-Comté BB-0033-00024”. Collec-
tion of samples and their use (AC-2010-1163) for studies
(approved by the scientific committee of “the tumorothè-
que régionale de Franche-Comté BB-0033-00024”) have
been approved by the French “ministère de la recherché”
and by the CPP EST II.We obtained all necessary consents
from any patients involved in the study.
Quantitative RT-PCR
RNA was isolated from cells and frozen tissues using Tri
Reagent (Molecular Research Center, TR-118) as described
by the manufacturer. Reverse transcription were performed
using M-MLV (Sigma-Aldrich, M-1302) reverse transcript-
ase and 1.5 μg total RNA according to manufacturer’s in-
structions (Sigma-Aldrich). Quantitative PCR (qPCR) were
done in duplicate using the Step one Real-Time PCR
system (Applied Biosystems), Power SYBR Green PCR
Master Mix (Applied Biosystems, 4367659), according
to manufacturer’s instructions and primers specific of
GABARAP (F: 5′-GCCTTTCCCATCCTGCTGTA-3′ and
R: 5′-AGGAGGGGATTGCTGGGTTCT-3′) ; GABAR-
APL1 (F: 5′-CCCTCCCTTGGTTATCATCCA-3′ and R:
5′-ACTCCCACCCCACAAAATCC-3′) and GABARAPL2
(F: 5′-AAATATCCCGACAGGGTTCC-3′ and R: 5′-CAG
GAAGATCGCCTTTTCAG-3′). H3B2 was used as an
housekeeping gene (F: 5′-GCTAGCTGGATGTCTTTT
GG-3′ and R: 5′-GTGGTAAAGCACCCAGGAA-3′) as
previously described [20].
Cell culture
MCF-7 and MDA-MB-453 cell lines were obtained from
ATCC (HTB-130 and HTB-22) and grown in DMEM
1 g/L glucose (Dominique Dutscher, L0066) containing
fetal calf serum (5 %) (Dominique Dutscher, S1810),
penicillin (50 U/ml) (Dominique Dutscher, L0018), strepto-
mycin (50 μg/ml), and amphotericin B (1.25 μg/ml) (PAA,
P11-001) at 37 °C in 5 % CO2, and routinely used at
70–80 % confluence. When indicated, cells were exposed
to 2 μM 5-aza-CdR (A3656, Sigma-Aldrich) for 48 h and
400 nM TSA (T8552, Sigma-Aldrich) for 16 h.
Luciferase activity
GABARAPL1 promoter fragments were obtained by PCR
using the following primers–336 F: 5′-GCTGGATCCC
AACCAGCAGGA-3′, −659 F: 5′-GTCAGGCTGGTCTC
GAACTC-3′ and +241 R: 5′-GGGATGCACCGCAGGG
CTTCC-3′ and then cloned into the pGL3 basic plasmid.
5000 cells were seeded in 96 multiwell dishes and cells
were transfected with pGL3 plasmids, co-transfected with
the pCDNA3.1-CREB-1 vector (kindly provided by Vincent
Coulon, Montpellier, France) or treated with 10 μM
forskolin. Luciferase expression was measured using the
Luciferase Assay System kit (E1500, Promega) according
to the manufacturer’s recommendations.
Epigenetics
gDNA was extracted using the NucleoSpin® Tissue kit
(740952, Macherey Nagel). Global DNA methylation was
quantified using the MethylFlash methylated DNA quan-
tification kit (P-1034, Epigentek, France). Methyl DNA
collection were performed using the “Methyl-Collector
Ultra kit” (55005, Active Motif ). Histone 3 acetylation
was quantified using the EpiQuik Tissue Acetyl-Histone
H3 ChIP Kit (P-2012, Epigentek). ChIP was performed
using the ChIP-IT High Sensitivity kit (53040, Active
Motif ) with ChIP grade antibodies (Table 1). All these
kits were used according to the manufacturer’s instruc-
tions. Primers used in this study were designed with the
primer3 software [21]: GABARAP (F: 5′-AAAGCCAACC
GTCTTTGCTA-3′ and R: 5′-GCCACTTCCCTATTCAC-
CAA-3′), GABARAPL1 (MC1 F: 5′-GTCAGGCTGGTC
TCGAACTC-3′ and R: 5′-CGCTCCTGAACAGCAACA
TA-3′) and GABARAPL1 (MC2 F: 5′-AAGGAAACGCA
GTGAGACAGA-3′ and R: 5′-AGCTGGGAGCACAAAA
ACAG-3′), GABARAPL2 (F: 5′AATTCCCCAGACTTCCC
CTA-3′ and R: 5′-GGTGGCGAAGAAGTTGGTTA-3′).
Western-blotting
Cells were scraped, harvested and lysed in RIPA buffer
(50 mM Tris–HCl, pH 8, 150 mM NaCl, 1 % Triton
×100, 0.5 % DOCA, 0.1 % SDS) supplemented with pro-
tease inhibitors (104 mM AEBSF, 1.5 mM pepstatin A,
Table 1 List of antibodies
Antibody Application Dilution Manufacturer Ref
GABARAP/GABARAPL1 WB 1:3000 (Millipore, France) #AB15278
GABARAPL2 WB 1:1000 (Proteintech, France) #18727-AP
ACTIN WB 1:3000 (Sigma-Aldrich, France) #A5060
CREB-1 IF/ChIP 1:50/1 μg (Santa-Cruz Biotechnology, France) #sc-374227
DNMT1 ChIP 1 μg (Active Motif, Belgium) #39204
HDAC1 ChIP 1 μg (Active Motif, Belgium) #40967
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1.4 mM E-64, 4 mM bestatin, 2 mM leupeptin, 80 μM
aprotinin) for 30 min on ice, sonicated for 15 sec and
centrifuged at 10 000 g for 10 min at 4 °C. Supernatant
was used for protein quantification using the Bradford
method [22] and then proteins (40 μg) were separated
using SDS-PAGE gels and transferred to PVDF mem-
branes (Bio-Rad, 162–0177) for 2 h in Tris-Glycine buffer
as previously described [23]. Membranes were saturated
in 0.1 % TBS-Tween 20 and 5 % nonfat milk for 1 h
and then incubated with primary antibodies (Table 1)
overnight at 4 °C. Membranes were washed 3 times
with TBS-Tween 20 0.1 %, incubated with secondary
anti-rabbit HRP conjugate or anti-mouse HRP conju-
gate antibody according to manufacturer’s instructions
(P.A.R.I.S., BI2407 and BI2413C). The membrane was
washed 3 times with TBS-0.1 % Tween 20 incubated
with ECL revelation buffer (Pierce) and cheluminescence
was monitored using a ChemiDocTMXRS+ (Biorad).
Immunofluorescence
CREB-1 IF was performed as precognized by the manu-
facturer. Briefly, cells were seeded on coverslips in 24
multiwell-plates, fixed and permeabilized for 20 min
with cold methanol at–20 °C, washed 3 times with cold
PBS (Phosphate buffer saline : 137 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4, 2 mM KH2PO4), incubated with
1 % BSA-PBS for 1 h at 37 °C and incubated overnight
with the CREB-1 antibody (Table 1). The coverslips were
washed 3 times for 5 min with 0.1 % Tween-PBS (T-PBS),
incubated for 1 h with a goat secondary anti-mouse
Alexa 555 antibody (Life technology, France) and washed
3 times for 5 min with (T-PBS). Cells were then mounted
in Vectashield Hardset mounting medium (Vector
Laboratories, H-1000) and analyzed using an Olympus
IX81 confocal microscope (Olympus, France).
Statistics
Mean’s comparison were analyzed using a Student t-test
with GraphPad Prism5 software (USA). Correlation in-
dexes were measured using a Spearman test with ImageJ
software. Significant values were highlighted in bold in
each figure.
Results
GABARAP family genes are differentially expressed in
human breast cancer biopsies
We first analyzed GABARAP, GABARAPL1 or GABAR-
APL2 mRNA expression in human BC biopsies using
qRT-PCR (Fig. 1). The different BC subtypes are classified
in regard of their molecular marker expression. Luminal
BC, which represent 50 % of total BC and generally associ-
ated with a good prognosis, are divided in Luminal A and
Luminal B BC. Both Luminal A and B BC express ERα (es-
trogen receptor: ER+) whereas the expression of the HER2
(HER+) (human epidermal growth factor receptor) gene
was only observed in Luminal B BC. HER+ BC subtype,
which represents 17 % of BC, presents an amplification of
the HER2 gene without the expression of ERα (ER-). The
triple negative BC (ER-/PR-/HER-) do not express ERα, PR
(progesterone receptor) and HER2 and cannot be treated
with specific therapies (for a review, see [24]). Our cohort
comprised 5 grade I BC (ER+/PR+/HER-) and 8 grade III
BC (5 ER-/PR-/HER-and 3 ER+/PR+/HER+). Our results
revealed an insignificant decrease of both GABARAP and
GABARAPL2 mRNA levels in grade III BC compared to
non tumoral tissue (NT). More interestingly, GABARAPL1
expression was strongly decreased in BC grade III tissues
(p = 0.004) versus non tumoral tissues. An inverse correl-
ation (r = −0.57) was also observed between GABARAPL1
mRNA and tumor stage while a very poor correlation
was determined between GABARAP or GABARAPL2
Fig. 1 GABARAP family expression is deregulated in breast cancers. Quantification of GABARAP, GABARAPL1, GABARAPL2 expression using qRT-PCR,
in grade I + II and grade III BC biopsies compared to normal adjacent tissue. Circle: NT (non tumoral), square: grade II, triangle: grade III. Difference
of expression were quantified using a t-test. The correlation between the tumor grade and gene expression was measured using a Spearman test
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expression levels and the tumor grade (respectively r =
−0.3 and r = −0.1).
Study of global and local epigenetic modifications in
GABARAPL1 promoter and GABARAPL1 expression in BC
tissues and cell models
Since tumors are frequently associated with aberrant
DNA methylation content, we quantified global DNA
methylation levels using ELISA in gDNA issued from
both grade III BC samples (associated with the lowest
expression of GABARAPL1 mRNA, as previously de-
scribed in Fig. 1 and NT tissues (Fig. 2a).7 [25, 26] As
expected, several gDNA issued from grade III BC pre-
sented a lower global DNA methylation compared to
gDNA issued from NT tissues. These results suggested
that epigenetic modifications might occur in these tumors.
To determine whether local DNA methylation was also al-
tered in these BC samples, methylation of XIST, a X-linked
gene known to be methylated in women, and GAPDH, a
gene constitutively active and unmethylated, were analyzed
by precipitation of methylated DNA using the methyl-
Collector Ultra kit. As expected, methylation of XIST
was observed in 100 % of both gDNA issued from NT
and grade I-II BC tissues tested but lost in 3 out of 5
Fig. 2 Detection of DNA methylation in GABARAP family promoters a Global DNA methylation quantification in BC and non tumoral biopsies
using methylFlash ELISA kit. b Scheme describing the GABARAP family gene promoter structure (Methprimer) and primer localization. c Left:
Descriptive of GABARAP family gene methylation using methylCollector kit ; right : examples of methylation signal observed using GABARAPL1
MC2 primers. White : absence of signal of methylation; black : signal of methylation. d Correlations (Spearman test) between expression and
methylation of GABARAP, GABARAPL1 and GABARAPL2 genes. NT: non tumoral, ER +/−: status of expression of estrogen receptor α, PR+/−: status
of expression of progesterone receptor, HER+/−: status of expression of Human epidermal growth factor receptor; I-III: BC grade
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triple negative BC biopsies (Grade III) (Additional file 1:
Figure S1). On the contrary, GAPDH was never found to
be methylated in NT gDNA but was surprisingly fre-
quently methylated in gDNA issued from BC samples
(Additional file 1: Figure S1). Loss of global DNA
methylation in several tissues (Fig. 2a 4 out 13 samples)
and aberrant status of methylation of XIST and GAPDH
(Additional file 1: Figure S1) strongly suggested that DNA
methylation was deregulated in BC samples.
We next analyzed whether epigenetic regulation of the
GABARAPL1 might explain its specific down-regulation
in BC. GABARAP, GABARAPL1 and GABARAPL2 present
CpG rich areas in their promoter (−800/+200) as predicted
using the methPrimer software [27], so we analyzed the
methylation status of these promoters using the methyl-
Collector Ultra kit (Fig. 2b and c). A low methylation sig-
nal was observed in both GABARAP and GABARAPL2
promoters (MC primers) both in tumors and NT tissues
while primers designed in the–800 region of GABARAPL1
(MC1) (Fig. 2c) revealed a strong signal of methylation in
both NT and BC tissues. Regarding GABARAPL1, a low
signal of unmethylation was also measured in NT samples
but not in BC samples suggesting that hemi-methylation
was lost in cancer cells (p = 0.0024) (Fig. 2c). To confirm
the higher level of methylation in the GABARAPL1 pro-
moter in BC, the same experiment was repeated using
primers (MC2) designed to detect the 5′-UTR region of
this gene. Results obtained with MC2 primers showed that
GABARAPL1 was not or weakly methylated in NT sam-
ples but highly methylated in BC tissues (p = 0.05) (Fig. 2c).
Pearson correlation analysis revealed that GABARAP
or GABARAPL2 expression was not correlated with
methylation status (r = −0.45, p = 0.12 and r = 0.36, p = 0.25
Fig. 2d), while GABARAPL1 expression was indeed cor-
related with the methylation status of the gene (r = −0.58,
p = 0.03 suggesting that methylation of the GABARAPL1
promoter may explain the downregulation of GABAR-
APL1 expression in BC (Fig. 2d).
In order to characterize the pathway allowing epigenetic
modifications to control GABARAP family expression, we
first analyzed GABARAP, GABARAPL1 and GABARAPL2
mRNA levels using qRT-PCR in MCF-7 and MDA-
MB-453 (BC cell lines) and MCF-10A (Breast immor-
talized but non tumoral cell line) cell lines (Fig. 3a).
Both GABARAP (p = 0.039), GABARAPL1 (p = 0.013) and
GABARAPL2 (p = 0.039) expression were decreased in
MCF-7 compared to MCF-10A but while the loss of
GABARAP or GABARAPL2 expression was weak (0.5-2
fold), GABARAPL1 expression was about 100-fold lower
in MCF-7 compared to MCF-10A (Fig. 3a). Similar results
were obtained for GABARAP, GABARAPL1 and GABAR-
APL2 in MDA-MB-453 cells but GABARAP did not show
any significant differences in this cell line (Fig. 3a). Methy-
lation of the GABARAP family promoters was then
assessed using the MethylCollector kit in both MCF-7 and
MDA-MB-453 cell lines presenting a low expression of
GABARAPL1. First, a signal of methylation of GABARAP
promoter was observed in MCF-7 cells but not in MDA-
MB-453 cells (Fig. 3b). Regarding GABARAPL2 promoter,
no methylation was detected in both cell lines. A high sig-
nal of methylation was detected in the GABARAPL1 pro-
moter in MCF-7 and MDA-MB-453 cells using MC1
primers confirming that the region of MC1 is highly
frequently methylated. As expected GABARAPL1 pro-
moter methylation was lost in MCF-7 cells treated with
5-aza-CdRdeoxycytidine (5-aza-CdR), a DNMTi (Fig. 3b).
A high signal of methylation was also detected using MC2
primers in MCF-7 cells but not in MCF-10A cells sug-
gesting, as observed before in human BC biopsies, that
GABARAPL1 methylation is predominantly observed in
BC cell lines (Fig. 3c)
As local DNA methylation is frequently associated to
histone deacetylation, the acetylation status of histone H3
(H3-ac) was analyzed by ChIP in MCF-7 and MDA-MB-
453 cells previously treated or not with trichostatin A
(TSA), an inhibitor of HDACs (Fig. 3d). ChIP analysis re-
vealed that H3 acetylation was detected in the GABARAP
promoter in MCF-7 cells but not in MDA-MB-453 cells.
A very low level of H3 acetylation was also observed in
GABARAPL2 promoter in these both cell lines. These sig-
nals were increased following TSA treatment in MCF-7
and MDA-MB-453 cells. Similarly, no H3 acetylation sig-
nal could be detected in the GABARAPL1 promoter of BC
cells but this signal was increased after TSA treatment,
particularly in the MDA-MB-453 cells (Fig. 3d).
All these data (Figs. 1, 2 and 3) suggest that GABAR-
APL1 is the most regulated gene of the GABARAP family
and that require promoter deacetylation and DNA methy-
lation. Interestingly, both DNMT1, which predominantly
catalyzes inheritance DNA methylation, and HDAC1 were
detected on GABARAPL1 promoter in MCF-7 cells using
ChIP experiments (Fig. 3e).
We next asked whether 5-aza-CdR or TSA could restore
GABARAPL1 expression in BC cell lines. To do so, MCF-7
and MDA-MB-453 cells were treated with 5-aza-CdR
or TSA and the levels of GABARAP, GABARAPL1 and
GABARAPL2 mRNA were measured using qRT-PCR
(Fig. 4a) while protein levels were quantified by western-
blotting (Fig. 4b). All cells were also treated with MG-132,
before protein extraction, to prevent the fast proteasomal
degradation of GABARAPL1 which has been previously
reported [28]. First we observed a not significant increase
of GABARAP mRNA (p = 0.07) but a significant increase
of the corresponding protein GABARAP (p = 0.007 and
p = 0.02) following TSA treatment in MCF-7 and MDA-
MB-453 cells. Both GABARAPL2 mRNA (p = 0.05 and
p = 0.05 respectively) and GABARAPL2 protein (p = 0.045
and p = 0.0003 respectively) were increased in MCF-7 and
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MDA-MB-453 cells treated with TSA. No significant effect
of 5-aza-CdR could be observed on GABARAP and
GABARAPL2 expression (Fig. 4a). On the opposite, 5-
aza-CdR treatment increased GABARAPL1 mRNA level
(about 2 fold) in both cell lines (p = 0.004 and p < 0.0001
respectively) while TSA treatment increased GABARAPL1
expression of 10 to 25 fold (Fig. 4a). Moreover, GABAR-
APL1 expression, which was undetectable in non treated
MCF-7 cells or 5-aza-CdR-treated cells, was increased fol-
lowing TSA treatment (Fig. 4b). A weak and diffuse band
signal corresponding to the GABARAPL1 protein was
also in over-exposed western-blotting using lysates of
MDA-MB-453 cells treated with TSA, suggesting that
GABARAPL1 might also be slightly increased in these
cells after TSA treatment.
Altogether these results confirm that GABARAPL1 is
the gene of the GABARAP family whose expression is the
most sensitive to epigenetic regulation in BC cell lines.
Since 5-aza-CdR and TSA treatments restored GABAR-
APL1 content, we next asked whether these compounds
modulate autophagy and cell proliferation in MCF-7 cells
(Additional file 2: Figure S2). Both an increase of LC3B-II
(form associated to the autophagosomes) (Additional
file 2: Figure S2A) and of cells with GFP-LC3 puncta
(Additional file 2: Figure S2B) were observed in respect-
ively 5-aza-CdR/ TSA treated cells and in GFP-LC3
transfected and TSA treated cells compared to control
cells. Moreover, both an decrease of cell proliferation
and clonogenecity were also observed in MCF-7 treated
cells (Additional file 2: Figure S2C and D). These results
suggest that restoration of GABARAPL1 expression
might be linked to these processes although some pleio-
tropic effects of 5-aza-CdR and TSA treatment could
also be involved [29].
Fig. 3 Epigenetic modifications in GABARAP family gene promoters. a Quantification of GABARAP, GABARAPL1, GABARAPL2 expression using qRT-PCR in
BC MCF-7 and MDA-MB-453 cancer cells and MCF-10A immortalized cells. b and c GABARAP family gene methylation using methylCollector
kit in MCF-7, MDA-MB-453 and MCF-10A cells. (I: input; M: methylated fraction). d Visualization of H3 deacetylation using ChIP experiment and
anti-H3 acetylated (H3-ac) antibody in the GABARAP family gene in MCF-7 and MDA-MB-453 cells (I: input; IgG: negative control of IP). e Detection of
DNMT1 and HDAC1 recruitment on GABARAPL1 promoter using ChIP experiment and anti-DNMT1 or anti-HDAC1 antibody (I: input; IgG :
negative control)
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GABARAPL1 expression is regulated by CREB-1
Behind epigenetic modifications of the promoter, the sec-
ond step of gene regulation is the recruitment of transcrip-
tional factors (TF). Therefore, in order to characterize the
mechanisms governing GABARAPL1 expression in these
cells, we cloned two fragments of the GABARAPL1
promoter (−659/+241 and −336/+241) in the pGL3 lu-
ciferase reporter plasmid. As suggested by 3 different
softwares (TESS http://www.cbil.upenn.edu/tess, Cis-
ter http://zlab.bu.edu/~mfrith/cister.shtml and Patch
http://www.gene-regulation.com/pub/programs.html#-
patch) used to predict TF binding sites, several putative
CRE (cAMP Response Element) elements were identified
in GABARAPL1 promoter (Fig. 5a). Indeed, following
transfection of our constructions in MCF-7 cells, we ob-
served a significant increase of luciferase signal in cells
transfected with the–336/+241-GABARAPL1-promoter-
pGL3 plasmid compared to the empty pGL3 vector
suggesting the presence of functional regulatory elements
in this region. Moreover, luciferase activity was strongly
increased when cells were transfected with the–659/+241-
GABARAPL1–promoter-pGL3 vector compared to the
basal–336/+241-GABARAPL1-promoter-pGL3 vector sug-
gesting that the region −659/-336 is also important for
GABARAPL1 regulation (Fig. 5b). Both treatment of
MCF-7 cells with forskolin, a compound known to acti-
vate CREB-1 (CRE binding protein-1), or transfection with
a plasmid expressing the CREB-1 protein significantly
increased luciferase activity linked to the construction–
659/+241-GABARAPL1–promoter-pGL3, suggesting that
CREB-1 is indeed involved in GABARAPL1 expression
(Fig. 5c). The increase of luciferase activity in cells
Fig. 4 Effects of epigenetic modulators on the GABARAP family gene expression. a Effects of 5-aza-deoxycytidine (5-aza-CdR) or trichostatin A
(TSA) on GABARAP family gene expression using qRT-PCR analysis. b Effects of 5-aza-CdR or TSA on GABARAP family protein expression using WB
(anti-GABARAP/GABARAPL1, anti-GABARAPL2 and anti-ACTIN antibodies) in cells previously treated with MG-132. Differences were quantified
using a t-test
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transfected with the pcDNA3.1-CREB-1 vector might be
explained by the low level of endogenous CREB-1 in
MCF-7 cells as observed in IF experiments (Fig. 5c) and
ChIP experiment also confirmed the recruitment of
CREB-1 on the–659/+241-GABARAPL1-promoter in spite
of the presence of a high background noise that may be
provoked by the presence of–659/+241-GABARAPL1-
promoter plasmid (Fig. 5d). We next asked whether
endogenous GABARAPL1 expression may be regulated
by CREB-1. Treatment of MCF-7 cells with Actinomycin
D revealed that the half-life of GABARAPL1 mRNA was
high (about 17 h) suggesting that regulation of GABAR-
APL1 mRNA content is more dependent on transcrip-
tion that mechanisms affecting mRNA stability (Fig. 5e)
Fig. 5 GABARAPL1 expression I controlled by CREB-1. a Scheme describing the position of primers used (in regard of the putative initial transcription
site (+1)) and putative CRE (CREB-1 response elements) sites in the GABARAPL1 promoter. b and c Luciferase activity measured using a Luciferase assay
System Kit in MCF-7 cells transfected with empty pGL3 plasmid,−336/+241-GABARAPL1-promoter-pGL3 plasmid,–659/+241-GABARAPL1-promoter-pGL3
plasmid, pCDNA3.1-CREB-1 or treated with (10 μM) forskolin. c Bottom : expression of CREB-1 using IF in cells transfected or not with the
pCDN3A.1-CREB-1 vector. d Recruitment of CREB-1 on–659/+241-GABARAPL1-promoter-pGL3 plasmid using ChIP experiment and anti-CREB-1
antibody in MCF-7 cells transfected with–659/+241-GABARAPL1-promoter-pGL3 and pCDNA3.1-CREB-1 plasmids (I: input; IgG : negative control of IP).
e Half-life of GABARAPL1 mRNA using qRT-PCR following Actinomycin D treatment in MCF-7 cells. f Effects of CREB-1 overexpression (following
pCDNA3.1-CREB-1 plasmid transfection) and/or 5-aza-CdR /TSA treatment on GABARAPL1 expression using qRT-PCR in MCF-7 cells. g Effects of
CREB-1 overexpression (following pCDNA3.1-CREB-1 plasmid transfection) and/or 5-aza-CdR/TSA treatment on CREB-1 recruitment in GABARAPL1
promoter using ChIP experiment and an anti-CREB-1 antibody (I: input; IgG : negative control). Differences were quantified using a t-tests. GL1: GABARAPL1
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[30, 31]. Moreover, overexpression of CREB-1 in MCF-
7 cells significantly increased GABARAPL1 expression
but at a lower level than the ones observed in cells
treated with 5-aza-CdR/TSA (Fig. 5f ). Moreover, a
non-significant (p = 0.066) further increase of GABAR-
APL1 expression was observed in cells transfected with
the CREB-1 plasmid and treated with 5-aza-CdR/TSA
compared to cells with 5-aza-CdR/TSA treatment alone.
These data suggest that epigenetic modifications may
be an initial predominant factor allowing the recruitment
of CREB-1 on GABARAPL1 promoter. These observations
were partly confirmed by ChIP experiments showing an in-
crease of CREB-1 recruitment on GABARAPL1 promoter
in MCF-7 cells previously treated with 5-aza-CdR/TSA.
But no significant difference could be observed between
5-aza-CdR/TSA treated cells transfected or not with the
vector encoding CREB-1 (Fig. 5g).
Discussion
While the role of autophagy in tumorigenesis is still
controversial, it is currently admitted that autophagy is
generally reduced in cancer cells. Whereas the origin of
the autophagy disruption is still unknown, mutations or
loss of heterozygosity-dependent autophagy gene silencing
(LC3, ATGs, UVRAG, BECN-1) have been reported in
many different cancers, such as colorectal, gastric car-
cinoma or breast cancers [32–36]. Besides mutations,
epigenetic modifications frequently occur in cancers, such
as global DNA hypomethylation and/or both local hypo
and hypermethylations in specific loci [37–39]. Hyper-
methylation of five autophagy-related genes, BECN-1,
ATG16L2, ULK2, BNIP3 and a variant of LC3A, were
previously reported respectively in BC, leukemia, astro-
cytoma, colorectal cancer and esophageal carcinoma and
these data demonstrated that this hypermethylation was
correlated to tumor grade [15–19]. Moreover, inhibition
of the HMT EZH2 or G9a promotes autophagy in cancer
cells while the use of HDACi gave contradictory results on
autophagy levels in cancer cells [12, 40].
Despite a high homology between the different mem-
bers of the GABARAP family (GABARAPL1 shows 87 %
identity with GABARAP and 61 % with GABARAPL2),
these proteins are differentially expressed during develop-
ment and in adult tissues (for review see [41]) and these
proteins have been described to be involved in several
molecular pathways, including receptor transport and
autophagy. Previous studies revealed that GABARAP
and GABARAPL1 may have redundant functions in
transport but experiments of invalidation/overexpression of
GABARAP and GABARAPL1 showed that both are re-
quired for autophagy [42, 43]. GABARAPL1 expression has
been described to be decreased in cancer cell lines. MCF-7
cells stably expressing exogenous Flag-GABARAPL1-
6His presents a significantly reduced proliferation rate
compared to control cells [6]. Other studies described
that a high expression of this gene is associated with a
positive outcome in metastatic BC [5, 6] while a low ex-
pression of GABARAPL1 was also associated with a
poor outcome in kidney carcinoma patients [44]. Our
results presented in this study confirmed these data by
showing an inverse correlation between GABARAPL1
expression and BC grade (Fig. 1). While GABARAP and
GABARAPL2 expression are also reduced in the tumor
samples, this decrease was not significant. Similar differ-
ences were observed between non tumoral MCF-10A cells
and MCF-7 BC cells since we showed a significant decrease
of GABARAP and GABARAPL2 expression in MCF-7 cells
but the highest decrease was observed for GABARAPL1.
Based on previous data reporting an epigenetic regulation
of BECN-1 in BC and our data showing a deregulation
of DNA methylation in our BC samples (Fig. 2a, and
Additional file 1: Figure S1), we hypothesized that the
loss of GABARAPL1 expression in BC might be linked
to epigenetic modifications. Indeed, DNA methylation
dependent gene silencing is frequent in BC and is highly
related to BC tumor genotypes (e.g. hypermethylation
of ESR1 in ERα negative patients), and may be essential
to determine the good treatment [45]. We report here
that the GABARAPL1 gene is highly methylated in
both–600 (MC1) and +200 (MC2) promoter regions but
the 5′-UTR +200 region presents the more significant
difference between non tumoral tissues/cells promoter
regions and tumoral/cancer cells since this region is poorly
methylated in normal tissue and frequently methylated in
tumors (Fig. 2). As described in previous studies, a correl-
ation between local DNA methylation and histone modifi-
cations is frequently observed in epigenetic-mediated gene
silencing [46, 47]. Our results confirm these observations,
since we observed that the promoter of GABARAPL1 pre-
sented a high level of methylated DNA and deacetylated
histone H3 (Fig. 3). On the other hand, DNA methylation
seemed poorly involved in GABARAP and GABARAPL2
expression while the inhibition of HDACs by TSA in-
creased H3 acetylation and increased GABARAP and
GABARAPL2 expression (Figs. 3 and 4).
Since the control of transcription factor accessibility in
the region close to the transcription initiation site is often
crucial for gene expression, we wondered whether it might
be important for the regulation of GABARAPL1 expression.
According to transcription binding site prediction soft-
wares, our data indeed revealed that GABARAPL1 ex-
pression is controlled by CREB-1 and that inhibition of
epigenetic repressive marks increased CREB-1-recruitment
on the GABARAPL1 promoter. Since CREB-1 has been
previously involved in the regulation of autophagy, the role
of this transcriptional factor may be crucial in this process.
Indeed, neuron protection mediated by CREB-1 activation
and associated with an increase of BECN-1 and LC3
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expression, was observed following rapamycin administra-
tion in ischemic neonatal rats [48]. On the opposite,
CREB-1 activation together with mTOR inhibitors has
also been described to potentiate chemotherapies in
renal cancers [49]. Nevertheless, the mechanism by which
CREB-1 can regulate autophagy and pro-survival signals
in cancer cells will require further studies.
Conclusion
The current use of epigenetic drugs in clinical trials pro-
vides new options for personalized adjuvant therapies in
cancers. Indeed, HDACi, such as Entinostat or valproic acid
efficiently increase ERα expression in ER-BC tumors and
considerably improve the efficiency of anti-estrogen signal-
ing therapies [50, 51]. 5-aza-CdR treatment has also been
previously reported to increase autophagy by inducing
LC3B-II in myeloid cells and myeloid cells resistant to 5-
aza-CdR presented an increase of basal autophagy [52]. An
increase of GABARAP family protein expression, following
5-aza-CdR/TSA treatment, might at least partly explain this
increase of autophagy levels. Indeed, GABARAP/GABAR-
APL1 overexpression in BC has been described to decrease
cell proliferation and tumorigenesis in nude mice [53, 54].
All these data strongly support the idea that autophagy
regulation may be a focal point for the design of combined
anti-cancer therapies in the future. Mahalingam et al. re-
cently proposed the evaluation of a combination of HDACi
(vorinostat) and autophagy inhibitor (hydroxychloroquine)
in a phase I study in patients with solid tumors [55]. How-
ever, identification of the molecular mechanisms governing
gene silencing in autophagy impairment in cancer will def-
initely help to develop future specific drugs, and decrease
the important side effects. Indeed, while DNMTi efficiently
restore ERα or BECN-1 expression in methylated tumors,
these compounds also reduce global DNA methylation and
local methylation [56]. DNMTi also strongly induce metal-
loproteinase expression in lymphoma and pancreatic can-
cers suggesting an increase of metastatic potential [57].
Similarly, urokinase, a marker of invasiveness associated
with the most aggressive BC and with prostate cancers is
increased after DNMTi treatment [58, 59].. In agreement
with previous studies on different autophagy related-genes,
our work demonstrated for the first time that the
GABARAP family genes, and particularly GABARAPL1, are
regulated by epigenetic modifications in BC and that epi-
genetic inhibitors might be used in combination with clas-
sical anti-chemotherapeutive drugs for futures anti-cancer
therapies.
Additional files
Additional file 1: Figure S1. XIST and GAPDH methylation status in BC.
XIST and GAPDH methylation was quantified using methylCollector kit.
NT: non tumoral, ER +/−: status of expression of estrogen receptor α,
PR+/−: status of expression of progesterone receptor, HER+/−: status of
expression of Human epidermal growth factor receptor. White : absence
of signal ; black : signal of methylation. (TIFF 77 kb)
Additional file 2: Figure S2. Effects of 5-aza-CdR/TSA treatment on
autophagy and cell proliferation. Increase of both cytosolic LC3-I and
autophagosome associated LC3-II forms detected by western blotting
using lysates of MCF-7 cells treated with 5-aza-CdR/TSA (antibody anti-LC3:
L8918, Sigma-Aldrich). (B) Increase of the number of cells presenting vesicles
in GFP-LC3 positive MCF-7 cells transfected with GFP-LC3 and treated with
5-aza-CdR or TSA. (C) A decrease of cell proliferation was observed in MCF-7
cells treated with 5-aza-CdR/TSA using the crystal violet/acid acetic method
as previously described [61]. (D) A decrease of clonogenecity was observed
in MCF-7 treated with 5-aza-CdR/TSA using the crystal violet method as
previously described [62]. (TIFF 122 kb)
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